Biohaven shares gave up nearly 15% in a single session on September 10, 2026 following the FDA’s partial clinical hold on new-patient enrollment in the BHV-7000/opakalim epilepsy trials

NEW YORK, Sept. 11, 2026 /PRNewswire/ — Biohaven Ltd (NYSE: BHVN) dropped $2.21, or about 14.73%, on September 10, 2026 after the Company disclosed that the FDA placed a partial clinical hold on new-patient enrollment in the Company’s BHV-7000/opakalim epilepsy trials. Shareholders who lost money on BHVN are encouraged to submit their losses for review now, or contact Joseph E. Levi, Esq. by telephone at (888) SueWallSt.

In BHVN’s release disclosing the partial hold, the Company indicated that “an update was provided to global regulatory authorities” regarding ongoing nonclinical studies and rodent testing. The FDA reportedly “determined that there was insufficient information related to a specific metabolite to assess risks.” As a result of the partial hold, new patient enrollment has been paused, but dosing will continue across patients “already randomized across the BHV-7000 program.”

Previously, on August 10, 2026, Biohaven’s provided business update highlighted the drug “continued to demonstrate a favorable safety profile” in its proof of concept study. On August 26, 2026, the Company announced a global licensing agreement with SK Biopharmaceuticals covering opakalim valued at up to approximately $795 million. Fifteen days later, the FDA hold was disclosed.

Investors who purchased Biohaven shares and suffered losses can have their BHVN losses evaluated at no cost or reach Joseph E. Levi, Esq. at jlevi@SueWallSt.com or (888) SueWallSt.

WHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

Frequently Asked Questions About the BHVN Investigation

Q: How much did BHVN stock drop?A: Shares fell approximately 14.73% on September 10, 2026 after the Company disclosed that the FDA had placed a partial clinical hold on new-patient enrollment in its BHV-7000/opakalim epilepsy trials. Investors who purchased shares and suffered losses may be eligible to seek recovery.

Q: Who is eligible to participate in the BHVN investigation?A: Investors who purchased BHVN stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses — not on whether you still hold the shares.

Q: Who is conducting the BHVN investigation?A: Levi & Korsinsky, LLP is investigating potential securities claims on behalf of investors who purchased BHVN securities. The firm is nationally recognized, ranked in the ISS Top 50 for seven consecutive years, and has recovered hundreds of millions of dollars for aggrieved investors.

Q: What do BHVN investors need to do right now?A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate?A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my BHVN shares — can I still recover losses?A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought BHVN and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate?A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys’ fees and expenses subject to court approval.

Q: What if I live outside the United States?A: U.S. securities investigations generally cover purchases on U.S. exchanges regardless of the investor’s country of residence.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@SueWallSt.com
Tel: (888) SueWallSt
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

View original content to download multimedia:https://www.prnewswire.com/news-releases/biohaven-investigation-notice-suewallst-notifies-investors-of-pending-investigation-into-biohaven-bhvn-302876666.html

SOURCE SueWallSt.com